培美曲塞二钠联合卡铂治疗非小细胞型肺癌的临床分析  

The Clinical Analyze of Curing Non Small Cell Lung Cancer by ALIMTA Combined with Carboplatin

作　　者：张建伟[1] 张宏艳[1] 亢玺刚[1] 张侠[1] 于忠和[1] 

机构地区：[1]北京军区总医院肿瘤科,北京100700

出　　处：《中国医药导刊》2012年第6期1054-1054,1056,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨培美曲塞二钠联合卡铂治疗非小细胞型肺癌的临床疗效。方法:回顾性分析80例非小细胞型肺癌患者临床资料,依据治疗方式不同分为对照组30例和观察组(培美曲塞二钠联合卡铂治疗组)50例。结果:观察组临床治疗总缓解率高于对照组,不良反应发生率低于对照组,P<0.05,差异有统计学意义。结论:美曲塞二钠联合卡铂治疗非小细胞型肺癌临床疗效明显,不良反应少。Objective：To approach clinical curative effect.Methods：To analyze clinical data of 80 cases Non small cell lung cancer,which were to be divided into control group 30 cases and detection group（ALIMTA combined with carboplatin curing group）50 cases.Results：The total remission rate of detection group were higher than control group,incidence of adverse reactions was lower than control group,P〈0.05,the difference were statistical significance.Conclusion：The clinical curative effect of curing Non small cell lung cancer by ALIMTA combined with carboplatin,the adverse reaction was little.

关 键 词：培美曲塞二钠 卡铂 非小细胞型肺癌 

分 类 号：R734.2[医药卫生—肿瘤]